Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by JayjayUSA12007on Jan 14, 2021 12:39am
149 Views
Post# 32291871

RE:RE:RE:RE:RE:It's time to protect long-term retail shareholders interest

RE:RE:RE:RE:RE:It's time to protect long-term retail shareholders interest There were so many mistakes during the past 10 years that we can't just ignore them.
After all, mistakes that keep repeating over and over would not be "mistakes". It's something else...
Time to have our voice heard, SPCEO.

SPCEO1 wrote: While I don't know for sure, I think I can say with a high degree of certainty, TH wanted to do an offering in the immediate aftermath of the general NASH announcement and conference call. But they botched the announcement (despite a really well scripted conference call) and the stock just yawned. Instead of learning from that pratfall and fixing their efforts to convince investors about the company's interesting prospects before doing an offering, they apparently were just panicking about the failure to get that offering off all this time. Our CEO declared they had many financing options - if this was the best of those many options, I am not sure he was telling us the truth the whole truth and nothing but the truth. As shareholders what we got was nothing at all like we were told. The board was indeed highly risk averse and failed to kick management into gear following that failed announcement on general NASH. They settled for failure and then compounded that failure with proceeding with this deal when in reality they had more time to set things right than they convinced themselves of. Many companies were able to raise money on better terms than these in April of last year. There was no need to panic and accept such distressingly bad terms. If they really had no better options in the current money for anyone environment, it just highlights what a failure their capital markets efforts have been. They evidently learned virtually nothing from the general NASH announcement debacle and that is far from encouraging. TH actually has a much better story to tell investors than many small biotechs, especially after announcing the phase III NASH news last week, they just have not got it done. They clearly need to do something very different in the future as the cost of this failure to shareholders will likely be measured in hundreds of millions of dollars in the long term.


<< Previous
Bullboard Posts
Next >>